CN102665606A - 用于生物医学用途的可注射水凝胶线丝 - Google Patents
用于生物医学用途的可注射水凝胶线丝 Download PDFInfo
- Publication number
- CN102665606A CN102665606A CN2010800532060A CN201080053206A CN102665606A CN 102665606 A CN102665606 A CN 102665606A CN 2010800532060 A CN2010800532060 A CN 2010800532060A CN 201080053206 A CN201080053206 A CN 201080053206A CN 102665606 A CN102665606 A CN 102665606A
- Authority
- CN
- China
- Prior art keywords
- barium sulfate
- hydrogel
- developing agent
- ethylenically unsaturated
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 70
- 239000000178 monomer Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 23
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 19
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 17
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 229920003224 poly(trimethylene oxide) Polymers 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- -1 tetramethyl aldehyde Chemical class 0.000 claims description 12
- 241001597008 Nomeidae Species 0.000 claims description 11
- 239000007943 implant Substances 0.000 claims description 11
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000005452 bending Methods 0.000 claims description 8
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 7
- 229910052788 barium Inorganic materials 0.000 claims description 7
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 230000007613 environmental effect Effects 0.000 claims description 5
- 230000004962 physiological condition Effects 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 235000011194 food seasoning agent Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000036244 malformation Effects 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 50
- 230000005855 radiation Effects 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000004020 conductor Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 241000399119 Spio Species 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000010533 azeotropic distillation Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000004846 x-ray emission Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004830 Super Glue Substances 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- PKZCRWFNSBIBEW-UHFFFAOYSA-N 2-n,2-n,2-trimethylpropane-1,2-diamine Chemical compound CN(C)C(C)(C)CN PKZCRWFNSBIBEW-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/50—Prostheses not implantable in the body
- A61F2/76—Means for assembling, fitting or testing prostheses, e.g. for measuring or balancing, e.g. alignment means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polymers & Plastics (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
Abstract
本文所述的是用具有延迟受控膨胀速率的辐射不透水凝胶线丝使结构和畸形闭塞的设备、组合物、系统和关联方法,其允许装置在结构或畸形内部的重新定位。还描述了一种用于植入动物体内的装置,包括双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体以及辐射不透元素,其中,所述装置不包含支撑部件。还公开了形成此类装置的方法。
Description
相关申请
本申请要求2010年7月13日提交的名称为Injectable Hydrogel Filaments for Biomedical Uses的美国临时申请序号61/363,978和2009年9月24日提交的名称为Injectable Hydrogel Filaments for Biomedical Uses的美国临时申请序号61/245,613的优先权,两者都通过引用结合到本文中。
技术领域
本发明一般地涉及医疗装置和方法,更特别地涉及在x射线荧光镜检查和可选地磁共振成像下可见的极其柔软的可注射水凝胶线丝以及将此类材料用于生物医学治疗的方法。
背景技术
目前,对于忍受极远侧血管中的脑和/或外周血管疾病(诸如动脉瘤、瘘或动静脉畸形(AVM))的病人而言,微介入神经放射科/神经外科医生具有多种栓塞选择:聚合物珠、聚乙烯醇泡沫颗粒、氰基丙烯酸酯胶合剂、可注射聚合液体以及柔软的可注射铂线圈。所有类型的栓塞剂都具有与之相关联的优点和缺点。聚合物珠和泡沫颗粒被容易地沿着流导向微导管注射,但是一般地在x射线荧光镜检查下是不可见的。氰基丙烯酸酯胶合剂和聚合液体常常提供足够的闭塞,但冒着使微导管的各部分永久地粘附在血管内部的风险。在授予Berenstein等人的美国专利号5,690,666中描述的柔软的可注射铂线圈容易部署且提供耐久的闭塞,但在磁共振成像(MRI)下是不可见的,并且不允许将计算机断层成像血管造影术(CT)用于病人跟踪。
尽管有这些栓塞选择,但仍存在对安全、极其柔软、可注射的栓塞装置的未满足的临床需要,其容易地通过流导向微导管部署到远侧血管中,导致耐久的血管闭塞,在x射线荧光镜检查、MRI下是可见的且允许CT跟踪。
发明内容
本文所述的是用包括一种或多种显影剂的具有延迟受控膨胀速率的柔软、可注射的水凝胶线丝使体腔中的结构和畸形闭塞的装置、组合物、系统和关联方法。该结构和畸形可能是任何数目的脑和/或外周疾病的结果。一般地,通过烯键式不饱和单体与可电离官能团(例如胺、羧酸类)的结合来赋予受控膨胀速率。例如,如果将丙烯酸结合到交联聚合网络中,则能够通过充满血液且或处于生理学pH的盐水的微导管来引入水凝胶,并且其在羧基去质子化之前将不会完全扩张。相反,如果将含胺的单体结合到交联网络中,则能够通过充满血液且或处于生理学pH的盐水的微导管来引入水凝胶,并且其在胺基质子化之前将不会完全扩张。
在一个实施例中,本文所述的是用于植入的装置,包括双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体、以及显影剂,其中,该装置不包含金属支撑部件。该装置可以具有柔性和硬度,其促进通过注射器用加压流体向身体中的远端位置进行注射。优选地,该装置在一英寸的样本长度上具有在0.5和0.1mg之间的抗弯曲性,并更优选地具有0.3 mg的抗弯曲性(用被附接到其测量静脉的5 g配重在Gurley 4171ET管状样本硬度测试器上测量)。
在一个实施例中,大单体具有约100克/摩尔至约5000克/摩尔的分子量。在另一实施例中,水凝胶是环境响应的。在另一实施例中,烯键式不饱和单体包括一个或多个可电离官能团。
在一个实施例中,大单体包括聚(四甲醛)双丙烯酰胺、聚乙二醇、丙二醇、聚(乙二醇)双丙烯酰胺、聚(乙二醇)双丙烯酸酯、聚(乙二醇)二甲基丙烯酸酯、其衍生物或其组合。在另一实施例中,烯键式不饱和单体包括N,N’-亚甲基双丙烯酰胺、N-乙烯基吡咯烷酮、2-甲基丙烯酸羟乙酯、其衍生物或其组合。
在一个实施例中,显影剂包括辐射不透元素,该辐射不透元素包括钡、钽、铂、金或其组合。在一个实施例中,显影剂包括钆或超顺磁性氧化铁以赋予在磁共振成像下的可见性。
在一个实施例中,显影剂是硫酸钡。在一个实施例中,所使用的硫酸钡的百分比在35-55%之间。在第一优选实施例中,所使用的硫酸钡的组分百分比是45.1%。在第二优选实施例中,所使用的硫酸钡的组分百分比是48.6%。
在一个实施例中,将预聚物溶液用均质器混合以均匀地分散显影剂,导致更一致的颗粒分布,促进到小直径管中的注射并加强所得到的聚合物。
在一个实施例中,大单体和单体的聚合是由偶氮二异丁腈、N,N,N’,N’-四甲基乙二胺、过硫酸铵、过氧化苯甲酰、2,2’-偶氮二异丁基脒二盐酸盐、其衍生物或其组合。
在另一实施例中,水凝胶是基本上非可生物再吸收的。在另一实施例中,水凝胶是可生物再吸收的。
本文所述的一个实施例是一种用于使装置准备好植入动物体内的方法,包括:将双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体、显影剂以及溶剂组合以制备预聚物溶液。
在该方法的一个实施例中,所述溶剂包括异丙醇、二氯甲烷、丙酮、水、乙醇或其组合。在另一实施例中,所述双官能低分子量烯键式不饱和可成形大单体具有约100克/摩尔至约5000克/摩尔的分子量。在另一实施例中,所述烯键式不饱和单体包括可电离官能团。
在一个实施例中,所述方法还包括向预聚物溶液添加第二烯键式不饱和单体的步骤。
在另一实施例中,描述了一种用于植入的装置,包括:具有约100克/摩尔至约5000克/摩尔的分子量的烯键式不饱和可成形大单体;烯键式不饱和单体和显影剂,其中,所述装置不包含金属支撑部件。
附图说明
从本发明的实施例的以下描述,本发明的实施例所能够实现的这些及其它方面、特征和优点将变得明显并得到阐述,对附图进行参考,在附图中:
图1示出了根据本发明的水凝胶线丝的优选实施例;
图2示出了处于螺旋配置的图1的水凝胶线丝;
图3示出了根据本发明的导引器中的图1的水凝胶线丝;以及
图4示出了经由微导管递送的图1的水凝胶线丝。
具体实施方式
现在将参考附图来描述本发明的特定实施例。然而,可以以许多不同形式来体现本发明,并且不应将其理解为局限于本文所阐述的实施例;相反,提供这些实施例,以便本公开将是透彻且完整的,并将全面地向本领域的技术人员传达本发明的范围。在附图所示的实施例的详细描述中所使用的术语并不意图限制本发明。在图中,相同的附图标记指示相同的元件。
除非另外定义,本文所使用的所有术语(包括技术和科学术语)具有与本发明所属领域的普通技术人员一般理解的相同的意义。还应理解的是诸如由一般使用的词典所定义的那些术语应被解释为具有与其在相关技术的上下文中的意义一致的意义,并且不应以理想化或过度形式化的意义来进行解释,除非本文明确地这样定义。
本文所述的是用于使由于一种或多种脑和/或外周血管疾病而引起的结构和畸形闭塞的装置、组合物、系统和关联方法。使用包括具有延迟、受控膨胀速率的一种或多种显影剂的水凝胶线丝来处理这些结构和畸形。此外,水凝胶线丝包括具有受控膨胀速率的一种或多种显影剂(例如辐射不透元素或填料),所述水凝胶线丝为外科医生提供充足时间量以通过充满血液或处于生理学pH的盐水的微导管来递送水凝胶,而不需要因为立即的线丝膨胀而仓促进行。
转到图1,以笔直配置示出了处于干燥状态的水凝胶线丝100的优选实施例。优选地,水凝胶线丝100具有在约0.5 cm与约100 cm之间的长度且具有在约0.008英寸与约0.100英寸之间的直径。一旦被递送到所选血管内部位,则水凝胶线丝100能够形成记忆设定、三维形状,诸如图2所示的螺旋形状。然而,应理解的是可以有多种不同的形状,诸如龙卷风形状、多个相邻线圈和类似的复杂布置。
如在图3中看到的,干燥水凝胶线丝100在治疗程序中的使用之前被定位于导引器102中。优选地,能够将导引器102和水凝胶线丝100杀菌并封装以便在日后使用。
当用户准备好开始该程序时,使用递送系统来递送水凝胶线丝。图4示出示例性递送系统,包括旋转止血阀114、引导导管116和微导管106。
微导管106在病人的脉管112中前进,直至微导管106的远端位于脉管112内的目标位置处。接下来,将导引器102的远端连接到递送系统并将导引器中心连接到注射器(未示出)。优选地,注射器包含供在病人体内使用的盐水或其它相容的生理溶液。
注射器在导引器102内递送加压溶液,从而使水凝胶线丝100前进到导引器102之外并进入微导管106。一旦水凝胶线丝100已完全进入微导管106,则可以从微导管106的近端去除导引器102并用饱含附加生理溶液的注射器进行替换。
当用户准备好递送水凝胶线丝100时,压下注射器,促使生理溶液在微导管106内加压并将水凝胶线丝100推入脉管112中,如在图4中看到的。优选地,水凝胶线丝100然后在目标区域处开始受控速率的膨胀。
一般地,通过烯键式不饱和单体与可电离官能团(例如酸性或碱性团)的结合来赋予水凝胶线丝的受控膨胀速率。例如,如果将丙烯酸被结合到交联聚合网络中,则能够通过充满血液且或处于生理学pH的盐水的微导管来引入水凝胶。在羧基去除质子化之前水凝胶不能且将不会膨胀。相反,如果将碱性的、包含胺的单体结合到交联网络中,则能够通过充满血液或处于生理pH的盐水的微导管来引入水凝胶。水凝胶不能且将不会完全膨胀,直到胺基被质子化。
在一个实施例中,根据本说明,无论在单体种类上利用酸性还是碱性团,本文所述的装置在生理条件下都是可膨胀的。本文所使用的生理条件意指具有在人体内或上发现的至少一个环境特性的条件。此类特性包括等渗压环境、pH缓冲环境、水相环境、约7的pH或其组合,并且能够在例如等渗压溶液、水、血液、脊髓液、血浆、血清、玻璃体液或尿中找到。
在一个实施例中,一般地,本文所述的是用于植入的装置,包括双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体、以及显影元素,其中,该装置不包含金属支撑部件。
此外,本文所述的装置不存在金属支撑部件允许在各种成像程序下具有更好的分辨率。例如,金属支撑部件能够通过在图像内产生来自金属支撑部件的闪光来使装置的成像失真。这样,如在本文中教授的,提供不具有金属支撑部件但包括一种或多种显影剂(诸如辐射不透元素或填料)的装置允许本领域的技术人员在植入期间和之后均获得装置的更精确和准确的图像。不具有金属支撑部件的此类装置可以包括对于成像技术而言不可见的支撑部件,例如聚合支撑部件。
在另一实施例中,本文所述的是一种用于使装置准备好植入动物体内的方法,包括步骤:将双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体、显影元素以及溶剂组合以制备预聚物溶液;以及处理预聚物溶液以制备能够在生理条件下膨胀的水凝胶。
一般地,预聚物溶液包括溶剂、双官能烯键式不饱和大单体、可选的烯键式不饱和单体、可选的交联剂以及一种或多种显影剂,诸如辐射不透元素或填料,其包括但不限于钡、钽、铂和金。
预聚物溶液中的溶剂用于使所有大单体和单体完全分散在预聚物溶液中。如果使用液体单体(例如2-甲基丙烯酸羟乙酯),则可以不需要溶剂。必要时,基于大单体和单体的可溶性来选择溶剂。优选溶剂是异丙醇(IPA、异丙醇)、乙醇、水、二氯甲烷和丙酮;然而,许多其它溶剂可以被采用且是本领域技术人员已知的。优选溶剂浓度在预聚物溶液的约10% w/w(重量比重量)至约50% w/w范围内。在一个优选实施例中,溶剂浓度为预聚物溶液的约20% w/w。
双官能低分子量烯键式不饱和可成形大单体用于在聚合期间使聚合物链交联并对所得到的聚合物赋予柔性。此类大单体包括两个烯键式不饱和基团。在一个实施例中,本文所述的大单体具有低分子量。本文所述的大单体具有从约100克/摩尔至约5000克/摩尔或约200克/摩尔至约2500克/摩尔、更优选地约400克/摩尔至约1000克/摩尔范围内的分子量。优选大单体是聚(四甲醛)双丙烯酰胺,这是由于其相对拉伸强度及其保持形状的能力。如果期望所得到的聚合物的降解,则优选大单体是聚(四甲醛)双丙烯酸酯。替代地,诸如聚醚聚(丙二醇)和聚(乙二醇)或诸如聚(乙烯)的聚烯烃衍生物的其它大单体是适当的。
本文所使用的“烯键式不饱和”一般地描述具有诸如但不限于乙烯基、丙烯酸酯、甲基丙烯酸酯或丙烯酰胺基团(包括其衍生物或其组合)的基团的化合物。
“可成形”大单体在本文中用来描述大单体的相对刚性及其保持特定形状的能力。例如,可以使用诸如心轴的装置来形成根据本说明的可成形大单体且其能够保持所得到的形状以进行植入。
“显影剂”在本文中用来指示被添加到或包括在本文所述装置内的任何元素,其赋予在植入期间或之后使装置显影的手段。显影方法包括但不限于x射线、超声、荧光镜检查、红外线辐射、紫外光方法、磁共振或其组合。在一个实施例中,显影剂可以是对本文所述装置赋予辐射不透性的一种或多种辐射不透元素或填料。在另一实施例中,显影剂可以是诸如钆或氧化铁的非辐射不透元素或填料。此类非辐射不透元素或填料不对本文所述的装置赋予辐射不透性且能够通过例如磁共振来成像。
本文所使用的“辐射不透”指的是如上所述的元素或填料,其对本文所述的装置赋予辐射不透性且可被诸如但不限于x射线、超声波、荧光镜检查、红外线、紫外线及其组合的电测辐射手段检测。在一个实施例中,本文所述的辐射不透元素是可使用x射线或x射线荧光镜检查来检测的。
可电离烯键式不饱和单体用于延迟水凝胶线丝的膨胀,从而确定受控膨胀速率。在一个实施例中,所选单体的至少一部分、优选地单体溶液的约1%至约10% w/w、更优选地预聚物溶液的约1%至约5% w/w是可电离的。优选可电离单体可以是丙烯酸或甲基丙烯酸。两个酸的衍生物或盐也是适当的可电离组分。替代地,在一个实施例中,不使用可电离烯键式不饱和单体。
在一个实施例中,使用可选的烯键式不饱和单体来辅助聚合过程且其可以是任何单或多官能烯键式不饱和化合物。在一个实施例中,具有低分子量的烯键式不饱和单体是优选的。甲基丙烯酸羟乙酯(例如2-丙烯酸羟乙酯)、丙烯酸羟乙酯、N-乙烯基吡咯烷酮和N,N’-亚甲基双丙烯酰胺是优选的烯键式不饱和单体。烯键式不饱和单体的优选浓度是小于预聚物溶液的约15% w/w、更优选地约10% w/w。
在一个优选实施例中,可以使用多官能烯键式不饱和化合物(诸如N,N-亚甲基双丙烯酰胺)的使用来进一步使聚合物基质交联。在一个优选实施例中,优选的组分百分比在高至1%的范围内。
在一个实施例中,除辐射不透元素之外,本文所述的水凝胶和装置还包括显影剂,诸如钆或超顺磁性氧化铁,以赋予装置在磁共振成像下的可见性。在其它实施例中,使用钆或超顺磁性氧化铁来代替辐射不透元素。
可以用氧化还原、辐射、加热或本领域中已知的任何其它方法来使预聚物溶液交联。可以在具有适当引发剂的情况下用紫外光或可见光或在没有引发剂的情况下用电离辐射(例如电子束或伽玛射线)来实现预聚物溶液的辐射交联。可以通过施加热量来实现交联,例如通过常规地使用诸如加热井的热源对溶液加热,或者通过向预聚物溶液施加红外光。
在优选实施例中,交联方法利用偶氮二异丁腈(AIBN)或另一溶于水的AIBN衍生物(2,2’-偶氮二异丁基脒二盐酸盐)。根据本说明可用的其它交联剂包括N,N,N’,N’-四甲基乙二胺、过硫酸铵、过氧化苯甲酰及其组合,包括偶氮二异丁腈。在一个实施例中,在高温下使用AIBN或其衍生物。
在添加AIBN之后,将预聚物溶液注射到具有从0.010英寸至0.075英寸范围内的内径的管中并在沸水、即100℃中培育几个小时。浸没在沸水中允许从水至包含在管中的预聚物溶液的快速热传递。管的选择赋予微导管或导管相容性。为了通过微导管递送,从约0.010英寸至约0.025英寸的管直径是优选的。在优选实施例中,管是由HYTREL?(特拉华州威尔明顿的DuPont)制成。HYTREL?管能够溶于溶剂中,促进从管去除聚合物。
在优选实施例中,在添加AIBN之前用均质器将预聚物溶液混合。
如果管在预聚物溶液的聚合之前缠绕在心轴周围,则所得到的聚合物将保持管的形状,主要是预聚物溶液内的可成形单体的结果。使用这种技术,可以对聚合物赋予螺旋、龙卷风和复杂的形状。所赋予的形状的记忆在很大程度上受到大单体选择的影响。更加憎水的大单体比更加亲水的大单体更好地保持其被赋予的形状。在本实施例中优选的是使用烯键式不饱和可成形大单体。
在优选实施例中,Hytrel管的内径被形成为具有椭圆形状。一旦被缠绕,则管的内径将随着管被压在心轴上而变圆。
在一个实施例中,本文所述的装置是环境响应的。本文所使用的环境响应指的是装置响应于周围环境以某种方式变化。在一个实施例中,对周围环境的此响应采取受控膨胀速率的形式。本文所述的水凝胶的受控膨胀速率是通过存在于水凝胶网络内或上的可电离官能团的质子化/去质子化实现的。
在已经洗涤交联水凝胶之后,将其干燥以产生干燥水凝胶线丝。长度可以在约0.5 cm至约100 cm范围内且直径可以在约0.008英寸至约0.100英寸范围内。为了制造流体辅助可注射栓塞装置,将干燥水凝胶线丝加载到导引器中,封装在适当的小袋中并进行杀菌。在接收到时,外科医生通过导引器注射盐水以去除空气。然后用充满盐水或其它生理溶液的注射器将干燥水凝胶线丝注射到微导管或导管中。该盐水或其它生理溶液被用来帮助使水凝胶线丝沿导管前进。然后用后续注射使干燥水凝胶线丝沿微导管或导管前进至栓塞部位。
在其它实施例中,水凝胶是非可生物再吸收的或基本上非可生物再吸收的。本文所使用的“非可生物再吸收”水凝胶是生物相容的且不会通过正常生物化学通道的作用经受活体内分解。在一个实施例中,水凝胶是基本上非可生物再吸收的且在植入1年之后仍有大于95%是完好的。在其它实施例中,基本上非可生物再吸收的水凝胶在1年之后仍有大于90%是完好的。
在另一实施例中,水凝胶是可生物再吸收的,意味着水凝胶是生物相容的且通过正常生物化学通道的作用而在活体内分解。在一个实施例中,水凝胶是可生物再吸收的且在植入1年之后留下小于5%是完好的。在其它实施例中,水凝胶是可生物再吸收的且在植入2年之后留下小于5%是完好的。在其它实施例中,水凝胶是可生物再吸收的且在植入5年之后留下小于5%是完好的。
示例
以下是本文所述的具有显影剂的水凝胶的某些生物医学应用的非限制性示例。然而,将认识到的是除本文所阐述的特定示例之外,此材料具有许多其它医学和非医学应用。
示例1
PTMO 1000双丙烯酰胺的制备
首先,通过用1100 mL的甲苯的共沸蒸馏来干燥150 g的聚(四甲醛)(PTMO)1000。然后,向50.2 mL的三乙胺添加27.9 mL的甲磺酰氯并搅拌达4小时。然后对溶液进行过滤以去除盐或对溶剂进行蒸发。将所得到的产物添加到1000 ml的乙腈和300 mL的25%氢氧化氨并搅拌达3天。去除水并通过用甲苯的共沸蒸馏来对产物进行干燥。使所得到的干燥PTMO二胺溶于1000 mL甲苯中。然后,添加46.0 mL的三乙胺和29.1 mL的丙烯酰氯且反应在搅拌的同时进行达4小时。过滤所得到的溶液并去除溶剂,留下PTMO 1000双丙烯酰胺。
示例2
Gd-DTPA甲基丙烯酸酯单体的制备
首先,将2.74 g的钆喷替酸葡甲胺连同2.1 g的乙基-3-(3-二甲基氨丙基)-碳二亚胺(EDC)和1.65 g的甲基丙烯酸乙酯一起溶于95 mL的水。将溶液调整至pH 8.0并搅拌达5小时。一旦反应完成,则在真空下对溶液进行循环蒸发以去除大部分水。将所得到的产物放置在真空烘箱中并完全干燥,留下钆喷替酸葡甲胺甲基丙烯酸酯。
示例3
10-sytem柔性钡加载辐射不透水凝胶线丝的制备
为了在有机溶剂中制备钡加载辐射不透水凝胶,将0.625 g的丙烯酸、6.25 g的聚(四甲醛)双丙烯酰胺1000、1.56 g的2-甲基丙烯酸羟乙酯、265 mg的N,N-亚甲基双丙烯酰胺和125 mg的偶氮二异丁腈溶于4.38 mL的异丙醇中。通过0.2微米注射器过滤器对溶液进行过滤。向10.56 g的溶液添加10 g的硫酸钡。这导致以下w/w组分百分比:PTMO 24.3%、AIBN 0.5%、HEMA 6.1%、丙烯酸2.4%、双丙烯酰胺1.0%、异丙醇17.0%以及硫酸钡48.6%。使用Ultra-Turrax T-25均质器来使溶液均质化。一旦被均质化,则在使用? cc注射器注射到缠绕在4 mm心轴周围的0.010英寸HYTREL?中之前用氩喷射溶液达10分钟。在两端处将管热密封并放置在100℃水浴中达1小时,然后在80℃烘箱中一整夜以使溶液聚合。所得到的线丝在干燥时具有0.008英寸的直径。
在溶剂的干燥和蒸发之后,最终植入物的重量百分比是PTMO 30%、HEMA 7%、丙烯酸3%、双丙烯酰胺1%和硫酸钡59%。
示例4
18-sytem柔性钡加载辐射不透水凝胶线丝的制备
为了在有机溶剂中制备钡加载辐射不透水凝胶,将0.625 g的丙烯酸、6.25 g的聚(四甲醛)双丙烯酰胺1000、1.56 g的2-甲基丙烯酸羟乙酯和125 mg的偶氮二异丁腈溶于4.38 mL的异丙醇中。通过0.2微米注射器过滤器对溶液进行过滤。向10.38 g的溶液添加8.5 g的硫酸钡。这导致以下w/w组分百分比:PTMO 26.5%、AIBN 0.5%、HEMA 6.6%、丙烯酸2.7%、异丙醇18.6%以及硫酸钡45.1%。使用Ultra-Turrax T-25均质器来使溶液均质化。一旦被均质化,则在使用3 cc注射器注射到缠绕在4 mm心轴周围的0.018英寸椭圆形HYTREL?中之前用氩喷射溶液达10分钟。在两端处将管热密封并放置在100℃水浴中达1小时,然后在80℃烘箱中一整夜以使溶液聚合。所得到的线丝在干燥时具有0.016英寸的直径。
在溶剂的干燥和蒸发之后,最终植入物的重量百分比是PTMO 30%、HEMA 8%、丙烯酸3%和硫酸钡56%。
示例5
PEG 1000双丙烯酰胺的制备
首先,通过用200 mL的甲苯的共沸蒸馏来干燥18 g的聚乙二醇(PEG)1000。然后,向7.0 mL的三乙胺添加4.6 mL的甲磺酰氯并搅拌达4小时。然后对溶液进行过滤以去除盐或对溶剂进行蒸发。将所得到的产物添加到150 ml的25%氢氧化氨并搅拌达2天。去除水并通过用甲苯的共沸蒸馏来对产物进行干燥。将所得到的干燥PEG二胺溶于20 mL二氯甲烷和50 mL甲苯中。然后添加7.0 mL的三乙胺和4.9 mL的丙烯酰氯并在搅拌的同时使反应进行达4小时。过滤所得到的溶液并去除溶剂,留下PEG 1000双丙烯酰胺。
示例6
水中Gd-DTPA水凝胶线丝的制备
为了在水中是被Gd-DTPA水凝胶线丝,将0.59 g的Gd-DTPA甲基丙烯酸酯、0.25 g的丙烯酸、5.25 g PEG双丙烯酰胺1000、0.125 g亚甲基双丙烯酰胺、6.0 g的硫酸钡、0.5 g的2-甲基丙烯酸羟乙酯和100 mg的2,2’偶氮二异丁基脒二盐酸盐溶于2.5 mL的水中。然后在使用3 cc注射器注射到缠绕在4 mm心轴周围的0.020英寸椭圆形HYTREL?中之前用氩喷射溶液达10分钟。在两端处将管热密封并放置在100℃水浴中达1小时,然后在80℃烘箱中一整夜以使溶液聚合。
示例7
水中SPIO水凝胶线丝的制备
为了在水中制备超顺磁性氧化铁(SPIO)水凝胶线丝,将0.953 mg的SPIO、0.25 g的丙烯酸、5.25 g PEG双丙烯酰胺1000、0.125 g亚甲基双丙烯酰胺、6.0 g的硫酸钡、0.5 g的2-甲基丙烯酸羟乙酯和100 mg的2,2’偶氮二异丁基脒二盐酸盐溶于2.5 mL的水中。然后在使用3 cc注射器注射到缠绕在4 mm心轴周围的0.020英寸椭圆形HYTREL?中之前用氩喷射溶液达10分钟。在两端处将管热密封并放置在100℃水浴中达1小时,然后在80℃烘箱中一整夜以使溶液聚合。
示例8
辐射不透水凝胶线丝的洗涤
通过使管溶解在氯仿中的20%苯酚的溶液中来去除水凝胶。在管被溶解之后,用氯仿交换酚溶液并洗涤达1小时。在1小时之后,交换氯仿并洗涤水凝胶再达1小时。去除氯仿并在50℃下在真空烘箱中对水凝胶干燥达2小时。为了去除任何未反应单体,将水凝胶放置在乙醇中达12小时。在12小时之后,交换乙醇并洗涤达2小时。在2小时之后,交换乙醇并洗涤水凝胶再达2小时。去除乙醇并在真空烘箱中干燥水凝胶达2小时。
示例9
抗弯曲性的测量
使用具有被附接到其测量叶片的5 g配重的Gurley 4171ET管状样本硬度测试机来获得未膨胀水凝胶样本的抗弯曲性。样本长度是一英寸。在下表中概括了用于三个复现试验的平均结果。
样本 | 测量到的抗弯曲性(mg) |
D-78辐射不透水凝胶线丝 | 0.3 ± 0.2 |
该结果说明用辐射不透水凝胶线丝能够实现可注射线圈所需的柔性。
虽然已根据特定实施例和应用描述了本发明,但本领域的技术人员根据本讲授内容能够在不脱离要求保护的本发明的精神或超出其范围的情况下产生附加实施例和修改。因此,应理解的是附图和本文的说明是以示例的方式提出的以促进本发明的理解,并且不应将其理解为限制本发明的范围。
Claims (41)
1.一种用于植入的装置,包括:
双官能低分子量烯键式不饱和可成形大单体;
烯键式不饱和单体;以及
显影剂,
其中,所述装置不包含支撑部件且具有在约0.5 mg和0.1 mg之间的抗弯曲性。
2.根据权利要求1所述的装置,其中,所述大单体具有约100克/摩尔至约5000克/摩尔的分子量。
3.根据权利要求1所述的装置,其中,所述水凝胶是环境响应的。
4.权利要求1所述的装置,其中,所述大单体包括聚(四甲醛)双丙烯酰胺、聚乙二醇、丙二醇、聚(四甲醛)、聚(乙二醇)双丙烯酰胺、聚(乙二醇)双丙烯酸酯、聚(乙二醇)二甲基丙烯酸酯、其衍生物或其组合。
5.根据权利要求1所述的装置,其中,所述烯键式不饱和单体包括一个或多个可离子化官能团。
6.根据权利要求1所述的装置,其中,所述烯键式不饱和单体包括N,N’-亚甲基双丙烯酰胺、N-乙烯基吡咯烷酮、2-甲基丙烯酸羟乙酯、其衍生物或其组合。
7.根据权利要求1所述的装置,其中,所述烯键式不饱和单体包括1% w/w的N,N’-亚甲基双丙烯酰胺。
8.根据权利要求1所述的装置,其中,所述显影剂包括48.6% w/w硫酸钡。
9.根据权利要求1所述的装置,其中,所述显影剂包括45.1% w/w硫酸钡。
10.根据权利要求1所述的装置,其中,所述显影剂在干燥之后包括59%硫酸钡。
11.根据权利要求1所述的装置,在干燥之后还包括约30% PTMO、约7% HEMA、约3%丙烯酸、约1%双丙烯酰胺以及约59%硫酸钡。
12.根据权利要求1所述的装置,其中,所述显影剂在干燥之后包括56%硫酸钡。
13.根据权利要求1所述的装置,在干燥之后还包括约33% PTMO、约8% HEMA、约3%丙烯酸以及约56%硫酸钡。
14.根据权利要求1所述的装置,其中,所述显影剂包括钆或氧化铁。
15.根据权利要求1所述的装置,其中,所述显影元素包括钡。
16.根据权利要求1所述的装置,其中,所述大单体和所述单体用N,N,N’,N’-四甲基乙二胺、过硫酸铵、偶氮二异丁腈、过氧化苯甲酰、2,2’-偶氮二异丁基脒二盐酸盐、其衍生物或其组合交联。
17.根据权利要求1所述的装置,其中,所述可电离官能团包括碱性团或酸性团。
18.根据权利要求15所述的装置,其中,所述可电离官能团包括胺基、其衍生物或其组合。
19.根据权利要求15所述的装置,其中,所述酸性团包括羧酸、其衍生物或其组合。
20.根据权利要求1所述的装置,其中,所述水凝胶基本上无丙烯酰胺。
21.根据权利要求1所述的装置,其中,所述水凝胶是基本上非可生物再吸收的。
22.根据权利要求1所述的装置,其中,所述水凝胶是可生物再吸收的。
23.一种用于使装置准备好植入动物体内的方法,包括:
a)将双官能低分子量烯键式不饱和可成形大单体、烯键式不饱和单体、显影剂以及溶剂组合以制备预聚物溶液;以及
b)处理所述预聚物溶液以制备水凝胶线丝,所述水凝胶线丝能够在生理条件下膨胀并具有在约0.5 mg和0.1 mg之间的抗弯曲性。
24.根据权利要求23所述的方法,其中,所述溶剂包括水、二氯甲烷、丙酮、异丙醇、乙醇或其组合。
25.根据权利要求23所述的方法,其中,所述双官能低分子量烯键式不饱和可成形大单体具有约100克/摩尔至约5000克/摩尔的分子量。
26.根据权利要求23所述的方法,其中,所述烯键式不饱和单体包括可离子化官能团。
27.根据权利要求23所述的方法,其中,所述溶剂包括所述预聚物溶液的约20% w/w至约80% w/w。
28.根据权利要求23所述的方法,其中,所述单体包括所述预聚物溶液的按重量计的约40%至约80%。
29.根据权利要求23所述的方法,其中,还包括向所述预聚物溶液添加第二烯键式不饱和单体的步骤。
30.根据权利要求23所述的方法,其中,所述溶剂被蒸发且所述显影剂包括59%硫酸钡。
31.根据权利要求23所述的方法,其中,所述溶剂被蒸发且所述水凝胶线丝为约30% PTMO、约7% HEMA、约3%丙烯酸、约1%双丙烯酰胺以及约59%硫酸钡。
32.根据权利要求23所述的方法,其中,所述溶剂被蒸发且所述显影剂包括56%硫酸钡。
33.根据权利要求23所述的方法,其中,所述溶剂被蒸发且所述水凝胶线丝在干燥之后为约33% PTMO、约8% HEMA、约3%丙烯酸以及约56%硫酸钡。
34.一种用于植入动物体内的装置,包括:
具有约100克/摩尔至约5000克/摩尔的分子量的双官能低分子量烯键式不饱和可成形大单体;
烯键式不饱和单体;以及
显影剂,
其中,所述装置不包含金属支撑部件且具有在约0.5 mg和0.1 mg之间的抗弯曲性。
35.根据权利要求34所述的装置,还包括硫酸钡。
36.根据权利要求35所述的装置,还包括48.6% w/w硫酸钡。
37.根据权利要求35所述的装置,还包括45.1% w/w硫酸钡。
38.根据权利要求35所述的装置,还包括在将所述装置的溶剂干燥之后的59%硫酸钡。
39.根据权利要求34所述的装置,还包括在干燥之后的约30% PTMO、约7% HEMA、约3%丙烯酸、约1%双丙烯酰胺以及约59%硫酸钡。
40.根据权利要求35所述的装置,其中,所述显影剂在干燥之后包括56%硫酸钡。
41.根据权利要求34所述的装置,还包括在干燥之后的约33% PTMO、约8% HEMA、约3%丙烯酸以及约56%硫酸钡。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24561309P | 2009-09-24 | 2009-09-24 | |
US61/245613 | 2009-09-24 | ||
US36397810P | 2010-07-13 | 2010-07-13 | |
US61/363978 | 2010-07-13 | ||
PCT/US2010/050296 WO2011038291A1 (en) | 2009-09-24 | 2010-09-24 | Injectable hydrogel filaments for biomedical uses |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102665606A true CN102665606A (zh) | 2012-09-12 |
Family
ID=43796241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800532060A Pending CN102665606A (zh) | 2009-09-24 | 2010-09-24 | 用于生物医学用途的可注射水凝胶线丝 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9114200B2 (zh) |
EP (1) | EP2480166B1 (zh) |
JP (2) | JP2013505791A (zh) |
KR (1) | KR20120090052A (zh) |
CN (1) | CN102665606A (zh) |
AU (1) | AU2010298026B2 (zh) |
CA (1) | CA2774646A1 (zh) |
WO (1) | WO2011038291A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115379866A (zh) * | 2020-03-31 | 2022-11-22 | 泰尔茂株式会社 | 栓塞剂 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101500623B (zh) | 2006-06-15 | 2016-08-24 | 微温森公司 | 一种由可膨胀聚合物构成的栓塞器械 |
CA2709379C (en) | 2007-12-21 | 2016-08-16 | Microvention, Inc. | Hydrogel filaments for biomedical uses |
EP2424775B1 (en) | 2009-04-30 | 2016-02-10 | Technip France | Spar mooring line sharing method and system |
EP2480166B1 (en) | 2009-09-24 | 2017-11-29 | Microvention, Inc. | Injectable hydrogel filaments for biomedical uses |
EP2493367B1 (en) | 2009-10-26 | 2019-03-13 | Microvention, Inc. | Embolization device constructed from expansile polymer |
WO2012145431A2 (en) * | 2011-04-18 | 2012-10-26 | Microvention, Inc. | Embolic devices |
US9011884B2 (en) | 2012-04-18 | 2015-04-21 | Microvention, Inc. | Embolic devices |
US10124090B2 (en) | 2014-04-03 | 2018-11-13 | Terumo Corporation | Embolic devices |
US10226533B2 (en) | 2014-04-29 | 2019-03-12 | Microvention, Inc. | Polymer filaments including pharmaceutical agents and delivering same |
US10092663B2 (en) | 2014-04-29 | 2018-10-09 | Terumo Corporation | Polymers |
TW201625754A (zh) * | 2014-11-21 | 2016-07-16 | 艾倫塔斯有限公司 | 單一成份、儲存穩定、可硬化之聚矽氧組成物 |
WO2016201250A1 (en) * | 2015-06-11 | 2016-12-15 | Microvention, Inc. | Expansile device for implantation |
EP3766436A4 (en) | 2018-03-29 | 2021-03-31 | TERUMO Kabushiki Kaisha | EMBOLICATE MATERIAL AND ITS MANUFACTURING PROCESS |
WO2021095834A1 (ja) | 2019-11-15 | 2021-05-20 | 学校法人慶應義塾 | X線不透過マイクロゲルファイバ |
JP7571124B2 (ja) * | 2020-03-31 | 2024-10-22 | テルモ株式会社 | 塞栓剤キット |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3749085A (en) * | 1970-06-26 | 1973-07-31 | J Willson | Vascular tissue removing device |
CS154391B1 (zh) * | 1970-09-10 | 1974-04-30 | ||
US4020829A (en) * | 1975-10-23 | 1977-05-03 | Willson James K V | Spring guide wire with torque control for catheterization of blood vessels and method of using same |
US4509504A (en) * | 1978-01-18 | 1985-04-09 | Medline Ab | Occlusion of body channels |
US4301803A (en) * | 1978-10-06 | 1981-11-24 | Kuraray Co., Ltd. | Balloon catheter |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4346712A (en) * | 1979-04-06 | 1982-08-31 | Kuraray Company, Ltd. | Releasable balloon catheter |
SE419597B (sv) * | 1979-05-04 | 1981-08-17 | Medline Ab | Anordning for temporer eller permanent tillslutning av kroppskanaler eller halrum hos menniskor och djur |
HU184722B (en) * | 1980-02-18 | 1984-10-29 | Laszlo Lazar | Therapeutically suitable silicone rubber mixture and therapeuticaid |
US4493329A (en) * | 1982-08-19 | 1985-01-15 | Lynn Crawford | Implantable electrode having different stiffening and curvature maintaining characteristics along its length |
GB8305797D0 (en) * | 1983-03-02 | 1983-04-07 | Graham N B | Hydrogel-containing envelopes |
US4529739A (en) * | 1984-07-24 | 1985-07-16 | The Dow Chemical Company | Foamed polymeric materials |
JPH0678460B2 (ja) * | 1985-05-01 | 1994-10-05 | 株式会社バイオマテリアル・ユニバース | 多孔質透明ポリビニルアルユールゲル |
US4795741A (en) * | 1987-05-06 | 1989-01-03 | Biomatrix, Inc. | Compositions for therapeutic percutaneous embolization and the use thereof |
US4819637A (en) * | 1987-09-01 | 1989-04-11 | Interventional Therapeutics Corporation | System for artificial vessel embolization and devices for use therewith |
US5165421A (en) * | 1987-09-30 | 1992-11-24 | Lake Region Manufacturing Co., Inc. | Hollow lumen cable apparatus |
US5154705A (en) * | 1987-09-30 | 1992-10-13 | Lake Region Manufacturing Co., Inc. | Hollow lumen cable apparatus |
US4932419A (en) * | 1988-03-21 | 1990-06-12 | Boston Scientific Corporation | Multi-filar, cross-wound coil for medical devices |
US4951677A (en) * | 1988-03-21 | 1990-08-28 | Prutech Research And Development Partnership Ii | Acoustic imaging catheter and the like |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5354290A (en) * | 1989-05-31 | 1994-10-11 | Kimberly-Clark Corporation | Porous structure of an absorbent polymer |
US5122136A (en) * | 1990-03-13 | 1992-06-16 | The Regents Of The University Of California | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US6425893B1 (en) | 1990-03-13 | 2002-07-30 | The Regents Of The University Of California | Method and apparatus for fast electrolytic detachment of an implant |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5133731A (en) * | 1990-11-09 | 1992-07-28 | Catheter Research, Inc. | Embolus supply system and method |
US5129180A (en) * | 1990-12-07 | 1992-07-14 | Landec Labs, Inc. | Temperature sensitive seed germination control |
US5120349A (en) * | 1990-12-07 | 1992-06-09 | Landec Labs, Inc. | Microcapsule having temperature-dependent permeability profile |
US6524274B1 (en) | 1990-12-28 | 2003-02-25 | Scimed Life Systems, Inc. | Triggered release hydrogel drug delivery system |
DE4104702C2 (de) * | 1991-02-15 | 1996-01-18 | Malte Neuss | Implantate für Organwege in Wendelform |
US5217484A (en) * | 1991-06-07 | 1993-06-08 | Marks Michael P | Retractable-wire catheter device and method |
CA2117088A1 (en) * | 1991-09-05 | 1993-03-18 | David R. Holmes | Flexible tubular device for use in medical applications |
US5226911A (en) * | 1991-10-02 | 1993-07-13 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5304194A (en) * | 1991-10-02 | 1994-04-19 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
JP3356447B2 (ja) * | 1991-10-16 | 2002-12-16 | テルモ株式会社 | 乾燥高分子ゲルからなる血管病変塞栓材料 |
US5258042A (en) * | 1991-12-16 | 1993-11-02 | Henry Ford Health System | Intravascular hydrogel implant |
DE69226203T2 (de) * | 1991-12-20 | 1998-12-10 | Alliedsignal Inc., Morristown, N.J. | Materialien mit niedriger dichte und hoher spezifischer oberflaeche und daraus geformte artikel zur verwendung in der metallrueckgewinnung |
US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5443478A (en) * | 1992-09-02 | 1995-08-22 | Board Of Regents, The University Of Texas System | Multi-element intravascular occlusion device |
US5469867A (en) * | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
AU4926193A (en) * | 1992-09-21 | 1994-04-12 | Vitaphore Corporation | Embolization plugs for blood vessels |
US5312415A (en) * | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
US5350397A (en) * | 1992-11-13 | 1994-09-27 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
US5382259A (en) * | 1992-10-26 | 1995-01-17 | Target Therapeutics, Inc. | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
US5382260A (en) * | 1992-10-30 | 1995-01-17 | Interventional Therapeutics Corp. | Embolization device and apparatus including an introducer cartridge and method for delivering the same |
US5690666A (en) * | 1992-11-18 | 1997-11-25 | Target Therapeutics, Inc. | Ultrasoft embolism coils and process for using them |
EP0746373A1 (en) * | 1992-12-01 | 1996-12-11 | Intelliwire, Inc. | Vibratory element for crossing stenoses |
CA2158731C (en) * | 1993-03-23 | 2001-06-05 | Stephen C. Rowe | Apparatus and method for local application of polymeric material to tissue |
US5554147A (en) * | 1994-02-01 | 1996-09-10 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
US5883705A (en) * | 1994-04-12 | 1999-03-16 | The Board Of Trustees Of The Leland Stanford, Jr. University | Atomic force microscope for high speed imaging including integral actuator and sensor |
US5483022A (en) * | 1994-04-12 | 1996-01-09 | Ventritex, Inc. | Implantable conductor coil formed from cabled composite wire |
US5573994A (en) * | 1994-05-13 | 1996-11-12 | University Of Cincinnati | Superabsorbent foams, and method for producing the same |
JP2535785B2 (ja) * | 1994-06-03 | 1996-09-18 | 工業技術院長 | 血管塞栓剤 |
EP1221307B1 (en) | 1994-07-08 | 2010-02-17 | ev3 Inc. | System for performing an intravascular procedure |
US5582610A (en) * | 1994-09-30 | 1996-12-10 | Circon Corporation | Grooved slider electrode for a resectoscope |
US5690671A (en) * | 1994-12-13 | 1997-11-25 | Micro Interventional Systems, Inc. | Embolic elements and methods and apparatus for their delivery |
US5578074A (en) * | 1994-12-22 | 1996-11-26 | Target Therapeutics, Inc. | Implant delivery method and assembly |
US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
WO1996022736A1 (en) * | 1995-01-27 | 1996-08-01 | Scimed Life Systems, Inc. | Embolizing system |
US5634936A (en) * | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
US5651979A (en) * | 1995-03-30 | 1997-07-29 | Gel Sciences, Inc. | Apparatus and method for delivering a biologically active compound into a biological environment |
US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
US5645558A (en) * | 1995-04-20 | 1997-07-08 | Medical University Of South Carolina | Anatomically shaped vasoocclusive device and method of making the same |
US6171326B1 (en) * | 1998-08-27 | 2001-01-09 | Micrus Corporation | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US5624461A (en) * | 1995-06-06 | 1997-04-29 | Target Therapeutics, Inc. | Three dimensional in-filling vaso-occlusive coils |
US5766160A (en) * | 1995-06-06 | 1998-06-16 | Target Therapeutics, Inc. | Variable stiffness coils |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6705323B1 (en) | 1995-06-07 | 2004-03-16 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US5725568A (en) * | 1995-06-27 | 1998-03-10 | Scimed Life Systems, Inc. | Method and device for recanalizing and grafting arteries |
EP0913124B1 (en) * | 1995-06-30 | 2003-11-26 | Boston Scientific Limited | Stretch resistant vaso-occlusive coils |
US5853418A (en) | 1995-06-30 | 1998-12-29 | Target Therapeutics, Inc. | Stretch resistant vaso-occlusive coils (II) |
US5582619A (en) * | 1995-06-30 | 1996-12-10 | Target Therapeutics, Inc. | Stretch resistant vaso-occlusive coils |
US6013084A (en) * | 1995-06-30 | 2000-01-11 | Target Therapeutics, Inc. | Stretch resistant vaso-occlusive coils (II) |
US5580568A (en) * | 1995-07-27 | 1996-12-03 | Micro Therapeutics, Inc. | Cellulose diacetate compositions for use in embolizing blood vessels |
JPH11510837A (ja) | 1995-07-28 | 1999-09-21 | フォーカル,インコーポレイテッド | 薬物送達のための制御された放出薬剤および組織処置薬剤としての使用のためのマルチブロック生分解性ヒドロゲル |
US5658308A (en) * | 1995-12-04 | 1997-08-19 | Target Therapeutics, Inc. | Bioactive occlusion coil |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
JP4104656B2 (ja) | 1995-12-19 | 2008-06-18 | ブラッコ・リサーチ・ソシエテ・アノニム | トリヨードベンゼンポリマーからなる胃腸管の画像形成用組成物 |
US5749894A (en) * | 1996-01-18 | 1998-05-12 | Target Therapeutics, Inc. | Aneurysm closure method |
US5702361A (en) | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
US5792154A (en) * | 1996-04-10 | 1998-08-11 | Target Therapeutics, Inc. | Soft-ended fibered micro vaso-occlusive devices |
WO1998001421A1 (en) | 1996-07-10 | 1998-01-15 | University Of Utah Research Foundation | pH SENSITIVE HYDROGELS WITH ADJUSTABLE SWELLING KINETICS FOR COLON-SPECIFIC DELIVERY OF PEPTIDES AND PROTEINS |
US6096034A (en) * | 1996-07-26 | 2000-08-01 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
US5980514A (en) * | 1996-07-26 | 1999-11-09 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
US5823198A (en) * | 1996-07-31 | 1998-10-20 | Micro Therapeutics, Inc. | Method and apparatus for intravasculer embolization |
AU4648697A (en) | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US5690667A (en) * | 1996-09-26 | 1997-11-25 | Target Therapeutics | Vasoocclusion coil having a polymer tip |
US5672634A (en) * | 1996-12-23 | 1997-09-30 | Isp Investments Inc. | Crosslinked PVP-I2 foam product |
US5853419A (en) * | 1997-03-17 | 1998-12-29 | Surface Genesis, Inc. | Stent |
CA2285457A1 (en) | 1997-04-02 | 1998-10-08 | Hoshi University | Method for oral delivery of proteins |
US6399886B1 (en) | 1997-05-02 | 2002-06-04 | General Science & Technology Corp. | Multifilament drawn radiopaque high elastic cables and methods of making the same |
US6860893B2 (en) | 1997-08-29 | 2005-03-01 | Boston Scientific Scimed, Inc. | Stable coil designs |
US6066149A (en) * | 1997-09-30 | 2000-05-23 | Target Therapeutics, Inc. | Mechanical clot treatment device with distal filter |
AU739610B2 (en) | 1997-11-07 | 2001-10-18 | Salviac Limited | Implantable occluder devices for medical use |
US6159165A (en) * | 1997-12-05 | 2000-12-12 | Micrus Corporation | Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand |
US6168570B1 (en) * | 1997-12-05 | 2001-01-02 | Micrus Corporation | Micro-strand cable with enhanced radiopacity |
US6136015A (en) * | 1998-08-25 | 2000-10-24 | Micrus Corporation | Vasoocclusive coil |
WO1999044538A1 (en) | 1998-01-27 | 1999-09-10 | The Regents Of The University Of California | Biodegradable polymer/protein based coils for intralumenal implants |
US7070607B2 (en) | 1998-01-27 | 2006-07-04 | The Regents Of The University Of California | Bioabsorbable polymeric implants and a method of using the same to create occlusions |
US5935145A (en) | 1998-02-13 | 1999-08-10 | Target Therapeutics, Inc. | Vaso-occlusive device with attached polymeric materials |
US6063100A (en) * | 1998-03-10 | 2000-05-16 | Cordis Corporation | Embolic coil deployment system with improved embolic coil |
US6015424A (en) * | 1998-04-28 | 2000-01-18 | Microvention, Inc. | Apparatus and method for vascular embolization |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
US5980550A (en) | 1998-06-18 | 1999-11-09 | Target Therapeutics, Inc. | Water-soluble coating for bioactive vasoocclusive devices |
KR20000012970A (ko) * | 1998-08-03 | 2000-03-06 | 김효근 | 썰폰아마이드기를 포함하는 ph 민감성 고분자 및 그의 제조방법 |
US6093199A (en) * | 1998-08-05 | 2000-07-25 | Endovascular Technologies, Inc. | Intra-luminal device for treatment of body cavities and lumens and method of use |
US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
JP4898991B2 (ja) | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | 被覆付植込式医療装置 |
US5952232A (en) * | 1998-09-17 | 1999-09-14 | Rothman; James Edward | Expandible microparticle intracellular delivery system |
US6187024B1 (en) | 1998-11-10 | 2001-02-13 | Target Therapeutics, Inc. | Bioactive coating for vaso-occlusive devices |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
EP1031354A3 (en) | 1999-01-19 | 2003-02-05 | Rohm And Haas Company | Polymeric MRI Contrast agents |
US6179857B1 (en) * | 1999-02-22 | 2001-01-30 | Cordis Corporation | Stretch resistant embolic coil with variable stiffness |
US20020169473A1 (en) | 1999-06-02 | 2002-11-14 | Concentric Medical, Inc. | Devices and methods for treating vascular malformations |
US6280457B1 (en) | 1999-06-04 | 2001-08-28 | Scimed Life Systems, Inc. | Polymer covered vaso-occlusive devices and methods of producing such devices |
US6312421B1 (en) | 1999-07-23 | 2001-11-06 | Neurovasx, Inc. | Aneurysm embolization material and device |
US6238403B1 (en) | 1999-10-04 | 2001-05-29 | Microvention, Inc. | Filamentous embolic device with expansible elements |
US6602261B2 (en) | 1999-10-04 | 2003-08-05 | Microvention, Inc. | Filamentous embolic device with expansile elements |
US6623450B1 (en) | 1999-12-17 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | System for blocking the passage of emboli through a body vessel |
AU2001245660B2 (en) | 2000-03-13 | 2006-06-15 | Biocompatibles Uk Limited | Embolic compositions |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
AU2001280618A1 (en) | 2000-07-18 | 2002-01-30 | George P. Teitelbaum | Biocompatible, expansile material and stent |
US6723108B1 (en) | 2000-09-18 | 2004-04-20 | Cordis Neurovascular, Inc | Foam matrix embolization device |
US7033374B2 (en) | 2000-09-26 | 2006-04-25 | Microvention, Inc. | Microcoil vaso-occlusive device with multi-axis secondary configuration |
US6537569B2 (en) | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
US6878384B2 (en) * | 2001-03-13 | 2005-04-12 | Microvention, Inc. | Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |
AU2002344223B2 (en) | 2001-05-29 | 2006-07-06 | Microvention, Inc. | Method of manufacturing expansile filamentous embolization devices |
AU2002359410A1 (en) | 2001-11-16 | 2003-06-10 | Biocure, Inc. | Methods for initiating in situ formation of hydrogels |
AU2003234159A1 (en) * | 2002-04-22 | 2003-11-03 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
US20040006354A1 (en) | 2002-07-02 | 2004-01-08 | Dean Schaefer | Coaxial stretch-resistant vaso-occlusive device |
US7608058B2 (en) | 2002-07-23 | 2009-10-27 | Micrus Corporation | Stretch resistant therapeutic device |
US20050171572A1 (en) | 2002-07-31 | 2005-08-04 | Microvention, Inc. | Multi-layer coaxial vaso-occlusive device |
EP1526815A1 (en) | 2002-07-31 | 2005-05-04 | MicroVention, Inc. | Three element coaxial vaso-occlusive device |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US20050119687A1 (en) | 2003-09-08 | 2005-06-02 | Dacey Ralph G.Jr. | Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels |
CN101415459B (zh) | 2004-08-25 | 2014-11-05 | 麦克罗文逊股份有限公司 | 可植入物装置的热脱离系统 |
US20060074370A1 (en) | 2004-09-24 | 2006-04-06 | Medennium, Inc. | Ocular occluder and method of insertion |
US20070202046A1 (en) * | 2006-02-24 | 2007-08-30 | Vipul Dave | Implantable device formed from polymer blends |
US20070288084A1 (en) * | 2006-06-09 | 2007-12-13 | Medlogics Device Corporation | Implantable Stent with Degradable Portions |
CN101500623B (zh) * | 2006-06-15 | 2016-08-24 | 微温森公司 | 一种由可膨胀聚合物构成的栓塞器械 |
US20100241160A1 (en) | 2007-06-11 | 2010-09-23 | Kieran Murphy | Method and kit for cyst aspiration and treatment |
CA2709379C (en) * | 2007-12-21 | 2016-08-16 | Microvention, Inc. | Hydrogel filaments for biomedical uses |
EP2480166B1 (en) | 2009-09-24 | 2017-11-29 | Microvention, Inc. | Injectable hydrogel filaments for biomedical uses |
EP2493367B1 (en) | 2009-10-26 | 2019-03-13 | Microvention, Inc. | Embolization device constructed from expansile polymer |
WO2012145431A2 (en) | 2011-04-18 | 2012-10-26 | Microvention, Inc. | Embolic devices |
-
2010
- 2010-09-24 EP EP10819570.2A patent/EP2480166B1/en not_active Not-in-force
- 2010-09-24 CA CA 2774646 patent/CA2774646A1/en not_active Abandoned
- 2010-09-24 WO PCT/US2010/050296 patent/WO2011038291A1/en active Application Filing
- 2010-09-24 JP JP2012531085A patent/JP2013505791A/ja active Pending
- 2010-09-24 KR KR20127008214A patent/KR20120090052A/ko not_active Withdrawn
- 2010-09-24 CN CN2010800532060A patent/CN102665606A/zh active Pending
- 2010-09-24 AU AU2010298026A patent/AU2010298026B2/en not_active Ceased
- 2010-09-24 US US12/890,540 patent/US9114200B2/en active Active
-
2014
- 2014-09-02 JP JP2014177973A patent/JP2014221432A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115379866A (zh) * | 2020-03-31 | 2022-11-22 | 泰尔茂株式会社 | 栓塞剂 |
Also Published As
Publication number | Publication date |
---|---|
CA2774646A1 (en) | 2011-03-31 |
EP2480166A1 (en) | 2012-08-01 |
EP2480166A4 (en) | 2014-04-30 |
AU2010298026A1 (en) | 2012-05-03 |
US9114200B2 (en) | 2015-08-25 |
JP2014221432A (ja) | 2014-11-27 |
WO2011038291A1 (en) | 2011-03-31 |
US20110212178A1 (en) | 2011-09-01 |
JP2013505791A (ja) | 2013-02-21 |
AU2010298026B2 (en) | 2015-11-05 |
KR20120090052A (ko) | 2012-08-16 |
EP2480166B1 (en) | 2017-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102665606A (zh) | 用于生物医学用途的可注射水凝胶线丝 | |
US11759547B2 (en) | Polymers | |
US10232089B2 (en) | Embolic devices | |
EP2231215B1 (en) | Hydrogel filaments for biomedical uses | |
US8734834B2 (en) | Acrylic hydrogels with deprotonated amine groups that undergo volumetric expansion in response to changes in environmental pH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120912 |